Lexeo Therapeutics

We are a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. Our team comes to work every day with a sustained commitment to improving human health - and it's what pushes us to innovate. At Deciphera, we are united in our goal to defeat cancer by addressing key mechanisms of tumor and drug resistance that limit the results of some existing therapies. We leverage our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. Since becoming a member of ONO Group in June 2024, we have continued expanding our global footprint while maintaining our dedication to patients. We design switch-control kinase inhibitors with the goal of potentially improving patient responses to treatment and, ultimately, patient outcomes.

Northwestern Medicine stands as a testament to over 160 years of healing innovation in the Chicago area. What began as a commitment to serve local communities has evolved into one of the nation's leading academic health systems, uniting world-class physicians, groundbreaking researchers, and compassionate care teams across 11 hospitals and more than 200 locations throughout Chicagoland. The organization represents the powerful collaboration between Northwestern Memorial HealthCare and Northwestern University Feinberg School of Medicine - a partnership that enables breakthrough discoveries to move swiftly from research laboratories to patient bedsides. At the heart of Northwestern Medicine lies a simple yet profound mission: to put patients first in all that they do, to make people better by making medicine better. This mission drives everything from their $67.5 million in annual charity care to their relentless pursuit of medical breakthroughs like pioneering lung repair techniques that have made them the nation's leader in lung transplants. Whether treating complex conditions at their nationally ranked hospitals or bringing primary care to neighborhoods through new outpatient centers, Northwestern Medicine combines academic excellence with compassionate care, ensuring that world-class medicine is always within reach of the communities they serve.

Flexxon is a Singapore-based industrial storage manufacturer founded in 2007 that has pivoted into hardware-level cybersecurity. The company manufactures NAND flash storage devices for industrial, medical, automotive, and cybersecurity applications - sectors where storage failure carries operational or safety consequences. Backed by Heliconia Capital Management, a Temasek Holdings subsidiary, Flexxon operates across Asia-Pacific, Europe, North America, and the Middle East, selling into environments that demand ruggedized hardware and verifiable data integrity under adverse conditions. The company's primary cybersecurity product is X-PHY, which Flexxon markets as an AI-embedded, firmware-based threat detection system that operates at the storage device level. The stated protection model targets ransomware, malware, and zero-day exploits by embedding threat detection directly into the firmware layer of storage hardware - positioning security below the operating system and application stack. This architectural approach attempts to address attacks that bypass software-based endpoint defenses or exploit firmware vulnerabilities in storage controllers, though independent validation of these protection claims is not detailed in available materials. Flexxon's technical focus spans industrial NAND flash engineering, firmware security architecture, and what it describes as embedded AI for real-time threat response within storage devices. The company frames its hardware-first security model as addressing gaps in traditional endpoint and network-layer defenses, particularly for critical infrastructure and OT environments where patching cycles are slow and downtime is costly. The integration of security functions directly into storage firmware represents an architectural bet that hardware-level controls can provide defense-in-depth against attacks targeting data at rest and during write operations. The company positions itself as serving the "C.I.M.A" verticals - cybersecurity, industrial, medical, and automotive - where data integrity requirements intersect with physical durability demands. Flexxon's evolution from a storage vendor into a security-focused manufacturer reflects broader industry movement toward hardware root-of-trust models and firmware-level defenses, particularly as supply chain attacks and pre-boot malware have demonstrated the limitations of software-only security stacks.

Click Therapeutics builds FDA-regulated software as medical treatment, shipping prescription apps to patients' smartphones. Since 2012, the 130-person company has navigated the regulatory gauntlet to clear CT-152 (Rejoyn™) - the first FDA-cleared prescription app for adjunctive Major Depressive Disorder - and advanced CT-132 through a successful pivotal trial for episodic migraine. The threat model here isn't traditional adversaries; it's patient safety, data integrity under FDA scrutiny, and the operational reality of deploying medical-grade software at scale. Mobile delivery means the attack surface lives in patients' hands, clinical data flows continuously, and every build touches PHI across four U.S. offices. The security architecture runs AES-256 encryption at rest and TLS 1.3 in transit, protecting data pipelines that feed AI and machine learning systems personalizing cognitive and behavioral interventions. API design connects clinical trial infrastructure, partner integrations with Otsuka Pharmaceutical and Boehringer Ingelheim, and the therapeutic delivery layer itself. The technical stack spans mobile app development, data analytics, and neuromodulatory software - domains where a breach doesn't just leak records, it undermines patient outcomes and regulatory standing. Operating across psychiatry, neurology, oncology, immunology, and cardiometabolic disease programs means securing diverse therapeutic workflows under a single compliance framework. The team operates at the intersection of software engineering, neuroscience, and FDA regulatory processes - building software that must clear clinical trials, maintain 21 CFR Part 11 compliance, and scale as prescription volume grows. Security here is foundational infrastructure, not bolt-on controls: the product is the treatment, and the data is the clinical evidence base.

Nexxis Solutions operates at the sharp end of defense software engineering, delivering system-level work directly to the Department of Defense and Intelligence Community across more than 30 active contracts. The company's technical remit spans the full spectrum of classified infrastructure needs: computer network operations, active defense, embedded engineering, reverse engineering, and information assurance. This isn't advisory theater - cleared engineers here work mission-critical systems where uptime and operational security are non-negotiable. The technical stack reflects the reality of modern defense work: Java, C, C++, and Python for core systems; containerized deployments via Kubernetes and Docker; big data tooling including Hadoop, Apache Spark, and MongoDB; and cloud infrastructure across AWS and Azure. Engineers engage with multi-sensor integration, large-scale data collection and analysis, high-performance computing environments, and increasingly, machine learning pipelines for operational intelligence. The threat model is state-level adversaries; the operational tempo is continuous. Founded by veterans from Praxis Engineering, Nexxis maintains technical depth in domains where precision matters - reverse engineering adversary capabilities, hardening enterprise IT infrastructure, and building systems for computer network operations. The work requires security clearances and operates under the constraints of classified environments, but the technical challenges are substantive: integrating heterogeneous sensor data at scale, engineering defensive capabilities that adapt to evolving threats, and building resilient systems that function under adversarial conditions.

At Rimac Automobili, we believe that extraordinary innovation comes from empowering teams to take real ownership of their work. Our engineers and designers operate with relentless curiosity, pushing boundaries from our state-of-the-art Rimac Campus - a €200M, 100,000-square-meter facility that embodies our commitment to excellence. We don't just build electric hypercars like the record-breaking Nevera; we nurture a culture where taking charge, embracing challenges, and learning continuously are part of our DNA. Every team member is expected to be self-driven and entrepreneurial, thriving in an environment where the impossible becomes reality through collaboration and bold thinking. Our people thrive here because we blend high-performance ambition with a humble, passionate approach to problem-solving. From our garage origins in 2009 to becoming a technology powerhouse working with partners like Porsche, Hyundai, and Aston Martin, we've maintained a spirit where fun fuels innovation and excellence is our benchmark. We empower every team member to lead at their level, fostering a culture that celebrates pushing technological limits while staying grounded in gratitude for our journey. At Rimac, you're not just building vehicles - you're helping redefine what's possible in automotive technology and electrification.